The protective effects of either IL-1 antagonization by IL-1RA application (Clausen et al., 2016; Maysami et al., 2016; Relton & Rothwell, 1992) or IL-1 (α/β) knockout in stroke have already been demonstrated in previous preclinical studies with IL-1 (α/β) knockout mice showing a 70% reduction in infarct volume after tMCAO (Boutin et al., 2001). Here, IL1B is linked to stroke disorder.